Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.78M | 14.25M | 16.63M | 12.87M | 9.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.78M | 14.25M | 16.63M | 12.87M | 9.11M |
| Cost of Revenue | 78.95M | 80.53M | 108.43M | 116.88M | 109.17M |
| Gross Profit | -65.17M | -66.29M | -91.80M | -104.00M | -100.06M |
| SG&A Expenses | 46.31M | 43.71M | 29.01M | 32.44M | 44.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.26M | 124.24M | 137.43M | 149.32M | 153.88M |
| Operating Income | -111.48M | -110.00M | -120.81M | -136.45M | -144.77M |
| Income Before Tax | -101.32M | -101.26M | -114.33M | -128.90M | -135.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.32M | -101.26M | -114.33M | -128.90M | -135.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.32M | -101.26M | -114.33M | -128.90M | -135.71M |
| EBIT | -111.48M | -110.00M | -120.81M | -136.45M | -144.77M |
| EBITDA | -106.54M | -107.52M | -118.31M | -133.88M | -142.16M |
| EPS Basic | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 |
| Normalized Basic EPS | -0.59 | -0.62 | -0.68 | -0.77 | -0.82 |
| EPS Diluted | -0.92 | -0.98 | -1.10 | -1.27 | -1.34 |
| Normalized Diluted EPS | -0.59 | -0.62 | -0.68 | -0.77 | -0.82 |
| Average Basic Shares Outstanding | 110.19M | 103.73M | 103.50M | 101.86M | 101.00M |
| Average Diluted Shares Outstanding | 110.19M | 103.73M | 103.50M | 101.86M | 101.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |